The Korea Times close
National
  • Politics
  • Diplomacy
  • Defense
  • Labor & Environment
  • Law & Crime
  • Health & Welfare
  • Embassy
  • Seoul & Provinces
  • Education
  • Foreign Communities
  • Obituaries
Biz & Tech
  • Auto
  • IT
  • Game
  • Manufacturing
  • Retail & Food
  • Energy
  • Construction
  • Airlines
Finance
  • Policies
  • Economy
  • Markets
  • Banks
  • Non-banks
Opinion
  • Editorial
  • Columns
  • Thoughts of the Times
  • Cartoon
  • Today in History
  • Blogs
  • Tribune Service
  • Blondie & Garfield
  • Letter to the Editor
Lifestyle
  • Arts
  • Books
  • Travel & Cuisine
  • Trend
  • Fashion
  • Around Town
  • Fortune Telling
Entertainment
  • K-pop
  • K-dramas & Shows
  • Movies
  • Music
  • Performances
  • Asia Model Festival
Sports
  • Football
  • Golf
  • Baseball
  • Other Sports
World
  • Asia Pacific
  • Americas
  • Europe & Africa
  • SCMP
Video
  • On the Spot
  • Feature
  • News
Photos
  • Photo News
  • Darkroom
Community
  • The Korea Times
  • search
  • Site Map
  • E-paper
  • Subscribe
  • Register
  • LogIn
search close
  • The Korea Times
  • search
  • Site Map
  • E-paper
  • Subscribe
  • Register
  • LogIn
search close
Finance
  • Policies
  • Economy
  • Markets
  • Banks
  • Non-banks
Thu, March 4, 2021 | 16:22
Markets
NeoImmuneTech's upcoming IPO at KOSDAQ
Posted : 2021-02-22 16:53
Updated : 2021-02-22 16:53
Mail
Print Preview
Font Size Up
Font Size Down
U.S.-based biopharmaceutical company NeoImmuneTech's CEO Yang Se-hwan speaks during the firm's IPO press conference held at the Conrad Seoul on Yeouido in the capital, Monday. Founded in 2014, the T-cell-focused company is dedicated to the discovery of novel immune-therapeutics in cooperation with major global pharmaceutical companies. The firm's stock allotment subscription period is for two days in early May and it's expected to make its KOSDAQ debut in mid-March. Courtesy of NeoImmuneTech
U.S.-based biopharmaceutical company NeoImmuneTech's CEO Yang Se-hwan speaks during the firm's IPO press conference held at the Conrad Seoul on Yeouido in the capital, Monday. Founded in 2014, the T-cell-focused company is dedicated to the discovery of novel immune-therapeutics in cooperation with major global pharmaceutical companies. The firm's stock allotment subscription period is for two days in early May and it's expected to make its KOSDAQ debut in mid-March. Courtesy of NeoImmuneTech



Emailannajpark@koreatimes.co.kr Article ListMore articles by this reporter









 
 
  • 2 people die after getting COVID-19 vaccine
  • Transgender ex-soldier forced to discharge found dead at home
  • 2 Korean nursing home residents die after getting AstraZeneca vaccine
  • Management of foreigners' ID to be strengthened
  • 'Chinese virus, get out!': Chinese lecturer assaulted in UK amid fears of anti-Asian racism
  • [INTERVIEW] 'We fight the gov't for our rights and future'
  • Hate crimes against Asian American on rise in US amid pandemic
  • Gov't to push for 'quarantine-free corridors' to support ailing aviation industry
  • Coupang Eats' new delivery fee policy hits riders
  • New virus cases bounce back to over 400
  • BLACKPINK's Rose to drop solo album next week BLACKPINK's Rose to drop solo album next week
  • Lee Seung-gi says new TV thriller series 'Mouse' is his 'most unique' piece Lee Seung-gi says new TV thriller series 'Mouse' is his 'most unique' piece
  • Ha Eun-byeol, 'The Penthouse: War in Life,' actress denies bullying accusation Ha Eun-byeol, 'The Penthouse: War in Life,' actress denies bullying accusation
  • BTS again tops Billboard's Artist 100 chart, sets record as group act BTS again tops Billboard's Artist 100 chart, sets record as group act
  • Gong Yoo, Park Bo-gum's 'Seobok' to hit theaters, streaming service in April Gong Yoo, Park Bo-gum's 'Seobok' to hit theaters, streaming service in April
DARKROOM
  • Bloody Sunday in Myanmar

    Bloody Sunday in Myanmar

  • Earth is suffering

    Earth is suffering

  • NASA's Perseverance rover is landing on Mars

    NASA's Perseverance rover is landing on Mars

  • Fun in the snow, sledding for everyone

    Fun in the snow, sledding for everyone

  • Our children deserve better: Part 3

    Our children deserve better: Part 3

  • About Korea Times
  • CEO Message
  • Times History
  • Content Sales
  • Media Kit
  • Contact Us
  • Location
  • Privacy Statement
  • Terms of Service
  • Mobile Service
  • RSS Service
  • 고충처리인
  • hankookilbo
  • Dongwha Group
  • Code of Ethics
Copyright